B · Normal
[Betta Pharmaceuticals: Ensartinib Hydrochloride Capsules were approved for marketing by the European Commission] On November 18, Beida Pharmaceuticals (300558.SZ) announced that the marketing authorization application for ensartinib hydrochloride capsules submitted by the company's holding subsidiary Xcovery was approved by the European Commission for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer. Ensartinib became the first domestic ALK inhibitor approved for marketing in China, the United States and the European Union.
Comments